United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

almirall ltd - tacalcitol monohydrate - cutaneous emulsion - 4microgram/1gram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

almirall ltd - tacalcitol monohydrate - cutaneous ointment - 4microgram/1gram

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

abbvie sdn bhd - paricalcitol -

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - paricalcitol 1ug - liquid filled capsule - 1 mcg - active: paricalcitol 1ug excipient: butylated hydroxytoluene ethanol gelatin glycerol medium-chain triglycerides purified water titanium dioxide - indicated in adult and paediatric patients 10 to 16 years of age for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. also indicated in adult patients for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease stage 5 in patients who are on haemodialysis or peritoneal dialysis.

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - paricalcitol 2ug - liquid filled capsule - 2 mcg - active: paricalcitol 2ug excipient: butylated hydroxytoluene ethanol gelatin glycerol iron oxide red medium-chain triglycerides purified water titanium dioxide - indicated in adult and paediatric patients 10 to 16 years of age for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. also indicated in adult patients for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease stage 5 in patients who are on haemodialysis or peritoneal dialysis.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

abbvie sdn bhd - paricalcitol -